Abbott Laboratories
NYSE:ABT
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
US |
Abbott Laboratories
NYSE:ABT
|
182.5B USD | 28.1 | ||
US |
Intuitive Surgical Inc
NASDAQ:ISRG
|
131.3B USD | 70.7 | ||
US |
Stryker Corp
NYSE:SYK
|
124.5B USD | 30.4 | ||
IE |
Medtronic PLC
NYSE:MDT
|
105.3B USD | 19 | ||
US |
Boston Scientific Corp
NYSE:BSX
|
98.8B USD | 43.9 | ||
US |
Becton Dickinson and Co
NYSE:BDX
|
67.4B USD | 39.1 | ||
DE |
Siemens Healthineers AG
XETRA:SHL
|
57.1B EUR | 30.6 | ||
US |
Edwards Lifesciences Corp
NYSE:EW
|
52B USD | 29 | ||
US |
Dexcom Inc
NASDAQ:DXCM
|
51.8B USD | 83.9 | ||
CN |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
327.1B CNY | 24.9 | ||
US |
IDEXX Laboratories Inc
NASDAQ:IDXX
|
39.7B USD | 36.5 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.